SE0102327D0 - A novel engineered superantigen for human therapy - Google Patents
A novel engineered superantigen for human therapyInfo
- Publication number
- SE0102327D0 SE0102327D0 SE0102327A SE0102327A SE0102327D0 SE 0102327 D0 SE0102327 D0 SE 0102327D0 SE 0102327 A SE0102327 A SE 0102327A SE 0102327 A SE0102327 A SE 0102327A SE 0102327 D0 SE0102327 D0 SE 0102327D0
- Authority
- SE
- Sweden
- Prior art keywords
- superantigen
- human therapy
- novel engineered
- engineered superantigen
- novel
- Prior art date
Links
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title abstract 4
- 231100000617 superantigen Toxicity 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/06—Message adaptation to terminal or network requirements
- H04L51/063—Content adaptation, e.g. replacement of unsuitable content
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/58—Message adaptation for wireless communication
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (31)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102327A SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | A novel engineered superantigen for human therapy |
US09/900,766 US7125554B2 (en) | 2001-06-28 | 2001-07-06 | Engineered superantigen for human therapy |
YU101503A RS52581B (en) | 2001-06-28 | 2002-06-19 | NEW CONSTRUCTED SUPERANTIGEN FOR HUMAN THERAPY |
PL368048A PL216516B1 (pl) | 2001-06-28 | 2002-06-19 | Koniugat obejmujący superantygen bakteryjny i część stanowiącą przeciwciało, zastosowanie tego koniugatu i kompozycja farmaceutyczna |
JP2003508382A JP4523773B2 (ja) | 2001-06-28 | 2002-06-19 | ヒト治療用新規組換えスーパー抗原 |
EP02746240.7A EP1406657B1 (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
MXPA03011761A MXPA03011761A (es) | 2001-06-28 | 2002-06-19 | Un nuevo superantigeno disenado para terapia humana. |
RU2004102199/13A RU2307837C2 (ru) | 2001-06-28 | 2002-06-19 | Новый биотехнологически созданный суперантиген для лечения человека |
BRPI0210568-3 BRPI0210568B8 (pt) | 2001-06-28 | 2002-06-19 | conjugado, uso de um conjugado, e, composição farmacêutica |
DK02746240.7T DK1406657T3 (en) | 2001-06-28 | 2002-06-19 | NEW TECHNICAL MADE superantigen TO TREAT PEOPLE |
HU0400313A HUP0400313A3 (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
CZ2003-3559A CZ307180B6 (cs) | 2001-06-28 | 2002-06-19 | Konjugát obsahující superantigen a protilátkovou skupinu, a farmaceutický prostředek s obsahem konjugátu |
CA2451847A CA2451847C (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
SK1611-2003A SK16112003A3 (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
ES02746240.7T ES2564041T3 (es) | 2001-06-28 | 2002-06-19 | Un nuevo superantígeno modificado genéticamente para terapia humana |
UA2004010601A UA85993C2 (ru) | 2001-06-28 | 2002-06-19 | Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего |
PCT/SE2002/001188 WO2003002143A1 (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
EEP200400037A EE05475B1 (et) | 2001-06-28 | 2002-06-19 | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon |
NZ529827A NZ529827A (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
IL15956202A IL159562A0 (en) | 2001-06-28 | 2002-06-19 | A novel engineered superantigen for human therapy |
KR1020037016268A KR100961054B1 (ko) | 2001-06-28 | 2002-06-19 | 암을 치료하기 위해 조작한 신규한 초항원을 포함하는 접합체, 이를 포함하는 조성물 및 이를 사용하는 방법 |
CN028131045A CN1522156B (zh) | 2001-06-28 | 2002-06-19 | 用于人类治疗的新型工程超级抗原 |
ZA2003/09150A ZA200309150B (en) | 2001-06-28 | 2003-11-25 | A novel engineered superantigen for human therapy |
HRP20031054AA HRP20031054B1 (hr) | 2001-06-28 | 2003-12-17 | Novo proizveden superantigen za humanu terapiju |
IS7083A IS2986B (is) | 2001-06-28 | 2003-12-18 | Nýr tilbúinn fjölræsivaki til að nota við meðferð á manneskjum |
NO20035773A NO333676B1 (no) | 2001-06-28 | 2003-12-22 | Nytt konstruert superantigen for human terapi |
BG108499A BG66321B1 (bg) | 2001-06-28 | 2003-12-22 | Генноинженерно получен конюгат за лечение на хора, който съдържа суперантиген |
IL159562A IL159562A (en) | 2001-06-28 | 2003-12-24 | Conjugate comprising a modified bacterial superantigen and an antibody moiety and use thereof in the treatment of cancer |
HK04110098.6A HK1067980A1 (en) | 2001-06-28 | 2004-12-21 | A novel engineered superantigen for human therapy |
US11/526,437 US7615225B2 (en) | 2001-06-28 | 2006-11-21 | Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen |
US12/568,579 US20100111978A1 (en) | 2001-06-28 | 2009-09-28 | Conjugates between a variant staphylococcal enterotoxin e superantigen and a targeting antibody that binds to a cancer-associated cell surface structure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102327A SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | A novel engineered superantigen for human therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0102327D0 true SE0102327D0 (sv) | 2001-06-28 |
Family
ID=20284677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0102327A SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | A novel engineered superantigen for human therapy |
Country Status (28)
Country | Link |
---|---|
US (3) | US7125554B2 (zh) |
EP (1) | EP1406657B1 (zh) |
JP (1) | JP4523773B2 (zh) |
KR (1) | KR100961054B1 (zh) |
CN (1) | CN1522156B (zh) |
BG (1) | BG66321B1 (zh) |
BR (1) | BRPI0210568B8 (zh) |
CA (1) | CA2451847C (zh) |
CZ (1) | CZ307180B6 (zh) |
DK (1) | DK1406657T3 (zh) |
EE (1) | EE05475B1 (zh) |
ES (1) | ES2564041T3 (zh) |
HK (1) | HK1067980A1 (zh) |
HR (1) | HRP20031054B1 (zh) |
HU (1) | HUP0400313A3 (zh) |
IL (2) | IL159562A0 (zh) |
IS (1) | IS2986B (zh) |
MX (1) | MXPA03011761A (zh) |
NO (1) | NO333676B1 (zh) |
NZ (1) | NZ529827A (zh) |
PL (1) | PL216516B1 (zh) |
RS (1) | RS52581B (zh) |
RU (1) | RU2307837C2 (zh) |
SE (1) | SE0102327D0 (zh) |
SK (1) | SK16112003A3 (zh) |
UA (1) | UA85993C2 (zh) |
WO (1) | WO2003002143A1 (zh) |
ZA (1) | ZA200309150B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
EA002688B1 (ru) * | 1997-07-21 | 2002-08-29 | Фармациа Энд Апджон Аб | Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов |
US7491402B2 (en) * | 1998-12-24 | 2009-02-17 | Auckland Uniservices Limited | Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
EP1578371A4 (en) * | 2002-08-19 | 2009-05-20 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
ATE461277T1 (de) * | 2003-03-28 | 2010-04-15 | Chemo Sero Therapeut Res Inst | Seb-modifikation und diese enthaltendes vorbeugendes mittel/heilmittel gegen krankheiten mit einer immunanomalität |
SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
EP1812574A2 (en) * | 2004-11-18 | 2007-08-01 | Avidex Limited | Soluble bifunctional proteins |
GB0427585D0 (en) * | 2004-12-16 | 2005-01-19 | Avidex Ltd | Assay |
US8455188B2 (en) * | 2007-01-26 | 2013-06-04 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012311492A1 (en) | 2011-09-23 | 2014-03-06 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5T4 and CD3 |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN102516392B (zh) * | 2011-11-25 | 2014-05-28 | 孙嘉琳 | 一种癌靶向超抗原融合蛋白及制备方法及用途 |
SG10201604896TA (en) | 2011-12-16 | 2016-08-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
JP2015513913A (ja) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ポリヌクレオチド |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
CN103965302B (zh) * | 2013-01-29 | 2019-05-28 | 军事科学院军事医学研究院微生物流行病研究所 | 一种重组超抗原seb突变体,其制备方法及应用 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
JP7161938B2 (ja) | 2016-01-10 | 2022-10-27 | ネオティーエックス セラピューティクス リミテッド | スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物 |
JP7303791B2 (ja) | 2017-07-27 | 2023-07-05 | アブヴァク インコーポレイテッド | スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物 |
EA202193121A1 (ru) | 2019-05-15 | 2022-02-21 | Неоткс Терапьютикс Лтд. | Лечение рака |
MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
EP4216982A2 (en) * | 2020-09-28 | 2023-08-02 | Janssen Pharmaceuticals, Inc. | Variant staphylococcusaureus luka and lukb polypeptides and vaccine compositions |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5221605A (en) | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US5284760A (en) | 1989-04-03 | 1994-02-08 | Feinstone Stephen M | Techniques for producing site-directed mutagenesis of cloned DNA |
US6042837A (en) | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6126945A (en) | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
WO1991010680A1 (en) | 1990-01-17 | 1991-07-25 | Terman David S | Tumor killing effects of enterotoxins and related compounds |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
ATE126535T1 (de) | 1990-04-05 | 1995-09-15 | Roberto Crea | ''walk-through''-mutagenese. |
US5858363A (en) | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
US6197299B1 (en) | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
WO1993024136A1 (en) | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
JPH06505486A (ja) | 1991-02-07 | 1994-06-23 | モレキュメティクス,リミティド | βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド |
CA2126438C (en) | 1991-12-24 | 2003-12-02 | Jac A. Nickoloff | Site-directed mutagenesis of dna |
US5389514A (en) | 1992-08-28 | 1995-02-14 | Fox Chase Cancer Center | Method for specifically altering the nucleotide sequence of RNA |
US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
US5519114A (en) | 1993-10-29 | 1996-05-21 | University Of Florida Research Foundation, Inc. | Retroviral superantigens, superantigen peptides, and methods of use |
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
US5935568A (en) | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US6632441B2 (en) | 1995-06-07 | 2003-10-14 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin a and methods of use |
US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
CN1080334C (zh) | 1996-03-27 | 2002-03-06 | 泽韦格路瓦有限公司 | 用于纱线的质量监控的方法和装置 |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US6447777B1 (en) | 1996-03-29 | 2002-09-10 | David S. Terman | Polymerized staphylococcal protein a for treatment of diseases |
ES2260804T3 (es) | 1996-12-06 | 2006-11-01 | Regents Of The University Of Minnesota | Mutante de la toxina estreptococica c y metodos de uso. |
US6913755B2 (en) | 1996-12-06 | 2005-07-05 | Regents Of The University Of Minnesota | Mutants of Streptococcal toxin A and methods of use |
US6774218B2 (en) | 1996-12-06 | 2004-08-10 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin C and methods of use |
WO1998026747A2 (en) | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
IL119938A (en) | 1996-12-30 | 2005-08-31 | Yissum Res Dev Co | Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells |
US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
EA002688B1 (ru) | 1997-07-21 | 2002-08-29 | Фармациа Энд Апджон Аб | Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов |
WO1999036433A2 (en) | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
AU758019B2 (en) | 1998-07-10 | 2003-03-13 | U.S. Medical Research Institute Of Infectious Diseases | Anthrax vaccine |
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
EP1242456B1 (en) * | 1999-11-18 | 2008-10-15 | Oxford Biomedica (UK) Limited | Scfv antibodies against disease associated molecules |
US20030157113A1 (en) | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US20010046501A1 (en) | 2000-03-14 | 2001-11-29 | Johnson Howard M. | Superantigen enhancement of specific immune responses |
JP4283430B2 (ja) | 2000-09-26 | 2009-06-24 | 株式会社カネカ | エンテロトキシンの吸着材、吸着除去方法および吸着器 |
AU1648102A (en) | 2000-12-04 | 2002-06-18 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
CN1369550A (zh) | 2001-02-16 | 2002-09-18 | 沈阳协合集团有限公司 | 一种金黄色葡萄球菌的培养物及其制备方法 |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
AU2003266289A1 (en) * | 2002-08-21 | 2004-03-11 | Merck Patent Gmbh | T-cell epitopes in staphylococcal enterotoxin b |
US20090162315A1 (en) * | 2004-06-29 | 2009-06-25 | Terman David S | Enterotoxin gene cluster (egc) superantigens to treat malignant disease |
US20060005711A1 (en) | 2004-07-07 | 2006-01-12 | Andrew Olefson | Replaceable filter for a vehicle air conditioning system adapted to scent air |
SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US20070280905A1 (en) * | 2006-06-01 | 2007-12-06 | Shulin Li | Prognosis and Systemic Therapy for Treating Malignancy |
-
2001
- 2001-06-28 SE SE0102327A patent/SE0102327D0/xx unknown
- 2001-07-06 US US09/900,766 patent/US7125554B2/en not_active Expired - Lifetime
-
2002
- 2002-06-19 RU RU2004102199/13A patent/RU2307837C2/ru active
- 2002-06-19 JP JP2003508382A patent/JP4523773B2/ja not_active Expired - Fee Related
- 2002-06-19 EE EEP200400037A patent/EE05475B1/xx not_active IP Right Cessation
- 2002-06-19 CN CN028131045A patent/CN1522156B/zh not_active Expired - Lifetime
- 2002-06-19 BR BRPI0210568-3 patent/BRPI0210568B8/pt not_active IP Right Cessation
- 2002-06-19 KR KR1020037016268A patent/KR100961054B1/ko active IP Right Grant
- 2002-06-19 HU HU0400313A patent/HUP0400313A3/hu unknown
- 2002-06-19 DK DK02746240.7T patent/DK1406657T3/en active
- 2002-06-19 PL PL368048A patent/PL216516B1/pl unknown
- 2002-06-19 RS YU101503A patent/RS52581B/en unknown
- 2002-06-19 ES ES02746240.7T patent/ES2564041T3/es not_active Expired - Lifetime
- 2002-06-19 NZ NZ529827A patent/NZ529827A/en not_active IP Right Cessation
- 2002-06-19 MX MXPA03011761A patent/MXPA03011761A/es active IP Right Grant
- 2002-06-19 CA CA2451847A patent/CA2451847C/en not_active Expired - Lifetime
- 2002-06-19 UA UA2004010601A patent/UA85993C2/ru unknown
- 2002-06-19 IL IL15956202A patent/IL159562A0/xx unknown
- 2002-06-19 WO PCT/SE2002/001188 patent/WO2003002143A1/en active IP Right Grant
- 2002-06-19 CZ CZ2003-3559A patent/CZ307180B6/cs not_active IP Right Cessation
- 2002-06-19 EP EP02746240.7A patent/EP1406657B1/en not_active Expired - Lifetime
- 2002-06-19 SK SK1611-2003A patent/SK16112003A3/sk unknown
-
2003
- 2003-11-25 ZA ZA2003/09150A patent/ZA200309150B/en unknown
- 2003-12-17 HR HRP20031054AA patent/HRP20031054B1/hr not_active IP Right Cessation
- 2003-12-18 IS IS7083A patent/IS2986B/is unknown
- 2003-12-22 NO NO20035773A patent/NO333676B1/no not_active IP Right Cessation
- 2003-12-22 BG BG108499A patent/BG66321B1/bg unknown
- 2003-12-24 IL IL159562A patent/IL159562A/en unknown
-
2004
- 2004-12-21 HK HK04110098.6A patent/HK1067980A1/xx not_active IP Right Cessation
-
2006
- 2006-11-21 US US11/526,437 patent/US7615225B2/en not_active Expired - Lifetime
-
2009
- 2009-09-28 US US12/568,579 patent/US20100111978A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0102327D0 (sv) | A novel engineered superantigen for human therapy | |
EP2371389A3 (en) | FcgammaRIIB-specific antibodies and methods of use thereof | |
TR200901979T2 (tr) | Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri. | |
MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
DE50202328D1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
HRP20080564T3 (en) | Dihydrotetrabenazines and pharmaceutical compositions containing them | |
MXPA05009682A (es) | Metodos de radiofluorinacion de vectores biologicamente activos. | |
TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
PT1261367E (pt) | Utilizacao de antagonistas da interleucina 6 para o tratamento de tumores dependentes de estrogenios | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
AU2002221908A1 (en) | Novel use of protein hydrolysates | |
NO20031860D0 (no) | Kahalaolid F | |
PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
MY130373A (en) | Linear basic compounds having nk-2 antagonist activity and formulations thereof | |
NO20010140L (no) | Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse | |
BR0010699A (pt) | Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários | |
ATE392644T1 (de) | Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen | |
MXPA03004111A (es) | Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion. | |
AU6722498A (en) | Disubstituted biphenyloxazolines | |
CY1111290T1 (el) | Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης | |
EP1370697A4 (en) | PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE | |
TR199902097A2 (xx) | Mikrobial transformasyon. | |
CY1105981T1 (el) | Ενωσεις 5-πυριδυλ-1,3-αζολιου, μεθοδοι παρασκευης αυτων και χρηση αυτων | |
RS51793B (en) | POLIMERNI conjugated HMGB1 HMGB1 VARIJANTI I BOX A BOX A |